Answers are grounded in this paper and cite their sources.
SG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety profile in patients with heavily pretreated, endocrine-resistant HR+/HER2- advanced breast cancer and limited treatment options.
No takes yet. Share an insight, caveat, or question.
Rugo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: